Fibrinogen-to-albumin ratio predicts mortality in COVID-19 patients admitted to the intensive care unit.

coronavirus disease 2019 fibrinogen-to-albumin ratio intensive care unit mortality

Journal

Advances in respiratory medicine
ISSN: 2543-6031
Titre abrégé: Adv Respir Med
Pays: Switzerland
ID NLM: 101697329

Informations de publication

Date de publication:
09 Dec 2021
Historique:
received: 30 03 2021
accepted: 13 06 2021
revised: 06 06 2021
entrez: 9 12 2021
pubmed: 10 12 2021
medline: 10 12 2021
Statut: aheadofprint

Résumé

Coronavirus disease 2019 (COVID-19) is an inflammatory disease, and serum albumin and fibrinogen are two important factors in systemic inflammation. We aimed to investigate the relationship between the fibrinogen-to-albumin ratio (FAR) and in-hospital mortality in COVID-19 patients admitted to the intensive care unit (ICU). Patients diagnosed with COVID-19 admitted to the Adiyaman Training and Research Hospital from August to November 2020 were enrolled in this retrospective cohort study. They were divided into 2 groups based on in-hospital mortality: a survivor group (n = 188) and a non-survivor group (n = 198). FAR was calculated by dividing the fibrinogen value by the albumin value. Mortality outcomes were followed up until December 15, 2020. The average age of the patients was 71.2 ± 12.9 years, and 54% were male. On multivariate logistic analysis, diabetes mellitus (OR: 1.806; 95% CI: 1.142-2.856; p = 0.011), troponin I levels (OR: 1.776; 95% CI: 1.031-3.061; p = 0.038), and FAR (OR: 1.004; 95% CI: 1.004-1.007; p = 0.010) at ICU admission were independent predictors of in-hospital mortality in patients with COVID-19. The FAR at admission was associated with mortality in patients infected with SARS-CoV-2 in the ICU.

Identifiants

pubmed: 34881805
pii: VM/OJS/J/75850
doi: 10.5603/ARM.a2021.0098
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Auteurs

Abdulmecit Afşin (A)

Department of Cardiology, Adiyaman Training and Research Hospital, Adiyaman, Turkey. abdulmecitafsin@gmail.com.

Hakan Tibilli (H)

Department of Cardiology, Adiyaman University Faculty of Medicine, Adiyaman, Turkey.

Yusuf Hoşoğlu (Y)

Department of Cardiology, Adiyaman Training and Research Hospital, Adiyaman, Turkey.

Ramazan Asoğlu (R)

Department of Cardiology, Adiyaman Training and Research Hospital, Adiyaman, Turkey.

Ahmet Süsenbük (A)

Department of Cardiology, Adiyaman University Faculty of Medicine, Adiyaman, Turkey.

Sezer Markirt (S)

Department of Cardiology, Adiyaman University Faculty of Medicine, Adiyaman, Turkey.

Verda Dinar Tuna (VD)

Department of Intensive Care Unit, Adiyaman Training and Research Hospital, Adiyaman, Turkey.

Classifications MeSH